2024

1. Autonomic dysfunction as manifestation of ICANS: A case report

   Medicine (United States), Vol. 103, Núm. 36, pp. e38659

2. Blast Transformation of Chronic Myeloid Leukemia Driven by Acquisition of t(8;21)(q22;q22)/RUNX1::RUNX1T1: Selecting Optimal Treatment Based on Clinical and Molecular Findings

   Biomedicines, Vol. 12, Núm. 10

3. CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs)

   Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25

4. Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosis

   Frontiers in Oncology, Vol. 14

5. Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 24, pp. 2873-2886

6. Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT)

   Cytotherapy, Vol. 26, Núm. 7, pp. 681-685

7. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes

   The Lancet Haematology, Vol. 11, Núm. 11, pp. e862-e872

8. Germline assessment for alloHSCT candidates over 50 years: A ‘Fast-Track’ screening in myeloid neoplasms

   British Journal of Haematology, Vol. 205, Núm. 2, pp. 503-509

9. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes

   Nature Communications, Vol. 15, Núm. 1

10. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet, Vol. 403, Núm. 10423, pp. 249-260

11. Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients

    Blood cancer journal

12. Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

    Blood, Vol. 144, Núm. 16, pp. 1722-1731

13. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee

    eClinicalMedicine, Vol. 69

14. Ligamentum flavum hematoma: A rare cause of cauda equina syndrome in older old patient

    Revista Espanola de Geriatria y Gerontologia, Vol. 59, Núm. 2

15. Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial

    The Lancet Haematology, Vol. 11, Núm. 9, pp. e659-e670

16. MOSAIC: An Artificial Intelligence-Based Framework for Multimodal Analysis, Classification, and Personalized Prognostic Assessment in Rare Cancers

    JCO Clinical Cancer Informatics, Vol. 8

17. Molecular profiling of pre- and post- 5-azacytidine myelodysplastic syndrome samples identifies predictors of response

    Frontiers in Oncology, Vol. 14

18. Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation

    JCO clinical cancer informatics, Vol. 8, pp. e2300205

19. Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

    Nature Communications, Vol. 15, Núm. 1

20. Targeting NOX2 and glycolytic metabolism as a therapeutic strategy in acute myeloid leukaemia

    Biomarker Research